A look at the IPO filings from April 12-April 19.<\/p>\n
<\/p>\n
NEW FILINGS<\/strong><\/p>\n Company: KCI Holdings, Inc. Company: Sonim Technologies, Inc. Company: ConversionPoint Holdings, Inc. Company: Milestone Pharmaceuticals Inc. Company: South Plains Financial, Inc. Company: Cortexyme, Inc. Company: Mayville Engineering Company, Inc. Company: Applied Therapeutics, Inc. Company: NextCure, Inc. Company: Parsons Corporation UPDATED TERMS NONE<\/p>\n","protected":false},"excerpt":{"rendered":" A look at the IPO filings from April 12-April 19.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-7821","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/7821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=7821"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/7821\/revisions"}],"predecessor-version":[{"id":7822,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/7821\/revisions\/7822"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=7821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=7821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=7821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSymbol: TBD
\nDescription: KCI is the leading global medical technology company focused on advanced wound care and specialty surgical applications.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, Goldman Sachs, BofA Merrill Lynch
\nFiled: 4-18-19
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: SONM
\nDescription: They are a leading U.S. provider of ultra-rugged mobile phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Oppenheimer, Lake Street
\nCo-Manager: National Securities
\nFiled: 4-15-19
\nListed Cash Raise: $57.5m<\/p>\n
\nSymbol: CPTI
\nDescription: They will be a newly-combined technology company with a mission to provide a first-party data driven, end-to-end, artificial intelligence (AI)-powered e-commerce platform not previously available to small and mid-size businesses, or SMBs.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Oppenheimer, GMP Securities
\nFiled: 4-15-19
\nListed Cash Raise: $40m<\/p>\n
\nSymbol: MIST
\nDescription: They are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Jefferies, Cowen, Piper Jaffray
\nFiled: 4-12-19
\nListed Cash Raise: $86.25m<\/p>\n
\nSymbol: SPFI
\nDescription: They are a bank holding company headquartered in Lubbock, Texas, and our wholly-owned subsidiary, City Bank, is one of the largest independent banks in West Texas.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Keefe Bruyette & Woods, Sandler O’ Neill
\nFiled: 4-12-19
\nListed Cash Raise: $50m<\/p>\n
\nSymbol: CRTX
\nDescription: They are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer\u2019s and other degenerative diseases.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): BofA Merrill Lynch, Credit Suisse
\nCo-Manager: Canaccord Genuity, JMP Securities
\nFiled: 4-12-19
\nListed Cash Raise: $86.25m<\/p>\n
\nSymbol: MEC
\nDescription: MEC is a leading U.S.-based value-added manufacturing partner that provides a broad range of prototyping and tooling, production fabrication, coating, assembly and aftermarket components.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Baird, Citigroup, Jefferies
\nCo-Manager(s): UBS Investment Bank, William Blair
\nFiled: 4-12-19
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: APLT
\nDescription: They are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Citigroup, Cowen, UBS Investment Bank
\nCo-Manager: Baird
\nFiled: 4-12-19
\nListed Cash Raise: $86.25m<\/p>\n
\nSymbol: NXTC
\nDescription: They are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch, Piper Jaffray
\nFiled: 4-12-19
\nListed Cash Raise: $86.25m<\/p>\n
\nSymbol: PSN
\nDescription: They are a leading provider of technology-driven solutions in the defense, intelligence and critical infrastructure markets.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, BofA Merrill Lynch, Morgan Stanley
\nCo-Manager(s): Jefferies, Wells Fargo, Cowen, SunTrust Robinson, MUFG, Scotiabank
\nFiled: 4-12-19
\nListed Cash Raise: $100m<\/p>\n
\n<\/strong><\/p>\n